Posted: 22 August 2024
INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has further validated its NEURONET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD).
On June 24th this year, INOVIQ reported that its NEURO-NET product successfully isolated brainderived exosomes from blood and identified a unique exosome protein fingerprint that differentiates Alzheimer’s disease (AD) from normal healthy blood samples.
NEURO-NET has now been shown to be effective in isolating brain-derived exosomes from blood samples of patients with Parkinson’s Disease and identifying a fingerprint of differentially expressed proteins compared to normal healthy individuals.
Initial analytical and clinical validation studies in PD showed:
- NEURO-NET enriches known protein biomarkers of neurodegenerative diseases by 5-8-fold compared to measuring them directly from blood, greatly increasing the potential for earlier detection of the onset of Parkinson’s disease.
- Analysis of NEURO-NET-captured exosomes, conducted by the Walter & Elisa Hall Institute, identified more than 200 proteins that were either decreased (blue) or increased (red) in PD patients when compared to normal healthy individuals (Fig 1, 10 cases and 10 controls).
CEO Leearne Hinch said: “NEURO-NET has now been validated to capture brain-derived exosomes and identify blood-based exosomal protein biomarkers in both Alzheimer’s Disease and Parkinson’s Disease. These biomarkers can be used to develop potential exosome-based blood tests for earlier detection and/or treatment selection of AD and PD. The next milestones for NEURO-NET include additional clinical validation data and collaborations with academia and industry in neurological diseases.”
Chairman David Williams said: “NEURO-NET is a next generation specialty product for isolation of brain-derived exosomes. NEURO-NET expands INOVIQ’s exosome capabilities and partnering opportunities to develop novel diagnostics for neurological conditions such as brain cancer, neuropsychiatric disorders and neurodegenerative diseases. INOVIQ is engaging with academia, diagnostic and biopharma companies to use our EXO-NET and NEURO-NET products for developing early detection or companion diagnostic tests for cancer and neurological conditions.”
